Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O’day Sells 9,810 Shares of Company Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel O’Day sold 9,810 shares of the company’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $175.17, for a total transaction of $1,718,417.70. Following the completion of the sale, the chief executive officer directly owned 551,683 shares in the company, valued at approximately $96,638,311.11. This represents a 1.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Wednesday, November 4th, Daniel O’Day sold 102,619 shares of Gilead Sciences stock. The shares were sold at an average price of $175.16, for a total transaction of $17,974,744.04.
• On Monday, November 2nd, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $169.74, for a total value of $2,546,100.00.
• On Friday, October 30th, Daniel O’Day sold 15,881 shares of Gilead Sciences stock. The stock was sold at an average price of $175.25, for a total value of $2,783,145.25.
• On Thursday, October 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $147.90, for a total transaction of $2,218,500.00.
• On Tuesday, September 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $148.64, for a total transaction of $2,229,600.00.

Gilead Sciences Stock Performance

GILD opened at $166.89 on Friday. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 0.95. Gilead Sciences, Inc. has a 12-month low of $116.88 and a 12-month high of $176.58. The stock’s 50-day moving average price is $153.04 and its 200 day moving average price is $140.94.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The company had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. During the same period in the prior year, the firm earned $2.47 EPS. The firm’s quarterly revenue was up 6.8% on a year-over-year basis. As a group, research analysts expect that Gilead Sciences, Inc. will post -1.07 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s payout ratio is currently -103.80%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of GILD. Cornerstone Advisory LLC bought a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $214,000. Aberdeen Group plc raised its holdings in Gilead Sciences by 3.1% in the third quarter. Aberdeen Group plc now owns 1,034,855 shares of the biopharmaceutical company’s stock worth $154,245,000 after buying an additional 31,340 shares during the last quarter. Compass Capital Management Inc. purchased a new stake in shares of Gilead Sciences during the 3rd quarter valued at about $245,000. Valmark Advisers Inc. grew its holdings in Gilead Sciences by 4.0% during the 3rd quarter. Valmark Advisers Inc. now owns 3,391 shares of the biopharmaceutical company’s stock valued at $505,000 after buying an additional 130 shares in the last quarter. Finally, Allworth Financial LP raised its holdings in shares of Gilead Sciences by 6.4% in the third quarter. Allworth Financial LP now owns 50,207 shares of the biopharmaceutical company’s stock worth $7,483,000 after buying an additional 3,015 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: New HIV-prevention data showed twice-yearly lenacapavir achieved nearly twice the one-year treatment persistence of daily oral F/TDF, a result that could support Gilead’s long-acting HIV-prevention strategy. Article: New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence
• Positive Sentiment: In the Phase 3 IDEAL study, Livdelzi (seladelpar) achieved ALP normalization in about 75% of participants with primary biliary cholangitis. The results may strengthen its case for broader second-line use, although the stock reportedly fell following the update. Article: Gilead’s Livdelzi Achieves 75% ALP Normalization
• Positive Sentiment: Recent third-quarter results beat analyst estimates for earnings and revenue, and Gilead raised full-year product-sales guidance. The company also maintained its quarterly dividend at $0.82 per share. Article: Did Earnings Beat Just Shift Gilead Sciences’ Investment Narrative?
• Neutral Sentiment: CEO Daniel O’Day sold more than 112,000 shares across November 4–5, but the transactions were conducted under a pre-arranged Rule 10b5-1 plan. He retained 551,683 shares, which may temper concerns about the sales. SEC Form 4 filing

Analyst Upgrades and Downgrades

GILD has been the subject of a number of recent research reports. Barclays cut their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 29th. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $170.00 to $190.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. TD Cowen increased their price objective on Gilead Sciences from $160.00 to $175.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Truist Financial raised their target price on Gilead Sciences from $158.00 to $181.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Finally, Wells Fargo & Company upped their price target on shares of Gilead Sciences from $165.00 to $190.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $170.15.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C.

Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.